China National Biotech Corporation (CNBC) is a research-driven biotech company that discovers, develops, manufactures and markets a broad range of human health products, including vaccines, blood derivatives, biopharmaceuticals, diagnostic reagents and others. The company is also a major player in China for the import and export of scientific and medical equipment and materials. CNBC is a state-owned company that works under the State-owned Assets Supervision and Administration Commission of State Council (SASAC) of People’s Republic of China and headquartered in Beijing, China.
CNBC consists of 6 renowned Institutes of Biological Products, which were formerly under the Ministry of Health, including National Vaccine and Serum Institute (NVSI), Changchun Institute of Biological Products (CIBP), Chengdu Institute of Biological Products (CDIBP), Lanzhou Institute of Biological Products (LIBP), Shanghai Institute of Biological Products (SIBP), Wuhan Institute of Biological Products (WIBP), and 2 international trading companies in Beijing, including China National Scientific Instrument and Materials Import & Export Corporation (CSIMC) and China National Medical Equipment and Supplies Import & Export Corporation (CNMC).
With more than 9,000 employees and worldwide revenues of 372 million USD in 2005, CNBC is the largest producer of vaccines and blood derivatives in China, enjoying more than 80% and 30% market share respectively. CNBC produced 800 million doses of vaccines in 2005 and ranked among top 10 vaccine companies in the world.
CNBC has 12 principal manufacturing sites strategically located in 6 cities around China. All manufacturing lines of CNBC have been granted with CGMP certificates from State Food and Drug Administration (SFDA) of China. The state-of-the-arts manufacturing facilities enable CNBC to expand into international markets as well as to be an ideal contractual manufacturer for business partners around the world.
CNBC’s R&D is based in 6 Institutes of Biological Products, among them NVSI is the oldest institute and was founded in 1919. The corporate R&D Center was established in Beijing on 18 January 2004 with the aim to maximize the synergies of all 6 Institutes. With more than 4,000 scientists and technicians in house, the company has also established a collaboration network with academic institutes and biotech companies through out China, Asia-Pacific, Europe, North America, and South America.